Abstract：
Bacillary dysentery (shigellosis) continues to cause havoc worldwide, with a high infectivity rate. It causes bloody diarrhea, and around 99% of bacillary dysentery cases occur in developing countries. The objective of this study is to develop a polyherbal formulation with the scientific rationale in treating infectious bacillary dysentery disease. The anti-bacterial activity, the minimum inhibitory concentration of the formulation against bacillary dysentery, causing microbes like Shigella flexneri (MTCC 1457), Escherichia coli (MTCC 1687), and Salmonella enterica (MTCC 98), was analysed by well-diffusion method and broth dilution method, respectively. The biofilm inhibition activity was determined on 96 well polystyrene plates and anti-quorum sensing activity by Chromobacterium violaceum CV026. The cytotoxicity was examined by acute oral toxicity. Excreta and organ bacterial load were analyzed by serial dilution method. The formulation efficacy was determined by analyzing the blood sample of rats. The antimicrobial efficacy of the developed formulation was calculated by measuring the zone of inhibition which was found to be 24 mm, 25 mm, and 25 mm, and the MIC values of 1.5 mg/ml, 1.5 mg/ml, and 2.0 mg/ml against S. flexneri, S. enterica, E. coli, respectively. The results show that the polyherbal formulation significantly reduced biofilm formation and has anti-quorum sensing activity. The formulation also effectively decreases the bacterial load and increases the K+, Na+, and Ca++ ions in animals treated with the formulation. The developed formulation was found to be non-toxic and effective against bacillary dysentery; thus, it can be used for treating bacillary dysentery and related complications.
摘要：
细菌性痢疾（志贺氏菌病）继续在世界范围内造成严重破坏，有很高的感染率。它会导致血性腹泻，约99%的细菌性痢疾病例发生在发展中国家。这项研究的目的是开发一种具有科学原理的多草药制剂，用于治疗感染性细菌性痢疾。抗菌活性,制剂对细菌性痢疾的最低抑制浓度，引起像福氏志贺氏菌（MTCC1457）这样的微生物，大肠杆菌（MTCC1687），和肠沙门氏菌（MTCC98），通过井扩散法和肉汤稀释法进行分析，分别。生物膜抑制活性在96孔聚苯乙烯板上测定，抗群体感应活性由紫罗兰色杆菌CV026测定。通过急性口服毒性检查细胞毒性。通过连续稀释法分析排泄物和器官细菌负荷。通过分析大鼠的血液样品来确定制剂功效。通过测量发现为24mm的抑制区来计算开发的制剂的抗微生物功效。25毫米,25毫米，MIC值为1.5mg/ml，1.5mg/ml,和2.0毫克/毫升对福氏杆菌，S、enterica，大肠杆菌，分别。结果显示,多草药制剂显著减少生物膜形成并具有抗群体感应活性。该制剂还有效降低细菌负荷并增加K+，Na+,和用该制剂处理的动物中的Ca++离子。发现开发的制剂无毒且有效对抗细菌性痢疾；因此，可用于治疗细菌性痢疾及相关并发症。
